enGene Therapeutics Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $-53.4M | $11.0M |
| FY2022 | — | $-76.6M | $20.4M |
| FY2023 | — | $72.5M | $81.5M |
| FY2024 | — | $272.6M | $173.0M |
| FY2025 | — | $167.7M | $50.2M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $-53.4M | $11.0M |
| FY2022 | — | $-76.6M | $20.4M |
| FY2023 | — | $72.5M | $81.5M |
| FY2024 | — | $272.6M | $173.0M |
| FY2025 | — | $167.7M | $50.2M |